Ptc Therapeutics Stock Analysis

PTCT
 Stock
  

USD 53.50  0.09  0.17%   

The newest price gain of Ptc Therapeutics may encourage private investors to take a closer look at the company as it is trading at a share price of 53.50 on 1,235,613 in trading volume. The company executives may have good odds in positioning the company resources to exploit market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.11. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Ptc Therapeutics partners.
Please check Your Equity Center.
  
The Ptc Therapeutics stock analysis report makes it easy to digest most publicly released information about Ptc Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Ptc Therapeutics Stock analysis module also helps to analyze the Ptc Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Ptc Therapeutics Stock Analysis Notes

About 106.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.84. Ptc Therapeutics recorded a loss per share of 7.38. The entity had not issued any dividends in recent years. PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. Ptc Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people. To find out more about Ptc Therapeutics contact Stuart Peltz at 908 222-7000 or learn more at www.ptcbio.com.

Ptc Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ptc Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ptc Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ptc Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 569.39 M. Net Loss for the year was (521.98 M) with loss before overhead, payroll, taxes, and interest of (34.42 M).
Ptc Therapeutics currently holds about 587.79 M in cash with (248.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.24.
Ptc Therapeutics has a poor financial position based on the latest SEC disclosures
Latest headline from simplywall.st: Shareholders might want to keep a close eye on PTC Therapeutics, Inc. after insiders sold US756k stock earlier this year - Simply Wall St

Ptc Therapeutics Upcoming and Recent Events

Earnings reports are used by Ptc Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ptc Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Ptc Therapeutics Largest EPS Surprises

Earnings surprises can significantly impact Ptc Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2018-08-07
2018-06-30-0.29-0.210.0827 
2013-11-14
2013-09-30-0.3-0.190.1136 
2015-11-09
2015-09-30-1.15-1.27-0.1210 
View All Earnings Estimates

Ptc Therapeutics Thematic Classifications

In addition to having Ptc Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

Ptc Therapeutics Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 3.51 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ptc Therapeutics's market, we take the total number of its shares issued and multiply it by Ptc Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Ptc Therapeutics Profitablity

Ptc Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Ptc Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Ptc Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Ptc Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Ptc Therapeutics' profitability requires more research than a typical breakdown of Ptc Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (91.68) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (52.38) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.52.
Last ReportedProjected for 2022
Return on Investment(58.90) (63.55) 
Return on Average Assets(25.27) (27.26) 
Return on Average Equity(216.75) (222.45) 
Return on Invested Capital(0.53) (0.57) 
Return on Sales(5.24) (5.38) 

Management Efficiency

The entity has return on total asset (ROA) of (11.99) % which means that it has lost $11.99 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (516.83) %, meaning that it created substantial loss on money invested by shareholders. Ptc Therapeutics management efficiency ratios could be used to measure how well ptc therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -63.55 in 2022. Return on Average Assets is likely to drop to -27.26 in 2022. Total Liabilities is likely to gain to about 2.1 B in 2022. Current Liabilities is likely to gain to about 549.6 M in 2022
Last ReportedProjected for 2022
Book Value per Share 6.00  6.47 
Enterprise Value over EBIT(5.40) (5.83) 
Enterprise Value over EBITDA(5.81) (6.27) 
Price to Book Value 4.42  4.27 
Tangible Assets Book Value per Share 12.38  12.71 
Enterprise Value956.6 M945.4 M
Tangible Asset Value328.8 M263.9 M

Technical Drivers

As of the 9th of August, Ptc Therapeutics holds the Risk Adjusted Performance of 0.2044, coefficient of variation of 663.94, and Semi Deviation of 2.76. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Ptc Therapeutics, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down nineteen technical drivers for Ptc Therapeutics, which can be compared to its competitors. Please check Ptc Therapeutics variance, as well as the relationship between the value at risk and skewness to decide if Ptc Therapeutics is priced some-what accurately, providing market reflects its current price of 53.5 per share. Given that Ptc Therapeutics has jensen alpha of 0.7121, we recommend you to check out Ptc Therapeutics's recent market performance to make sure the company can sustain itself at a future point.

Ptc Therapeutics Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Ptc Therapeutics price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.
.

Ptc Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ptc Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ptc Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ptc Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Ptc Therapeutics Technical and Predictive Indicators

Ptc Therapeutics Forecast Models

Ptc Therapeutics time-series forecasting models is one of many Ptc Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ptc Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Ptc Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ptc Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ptc Therapeutics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Ptc Therapeutics. By using and applying Ptc Therapeutics Stock analysis, traders can create a robust methodology for identifying Ptc Therapeutics entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(79.95) (86.26) 
EBITDA Margin(68.36) (73.76) 
Gross Margin 94.00  104.81 
Profit Margin(111.86) (120.69) 
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. Ptc Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people.

Current Ptc Therapeutics Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ptc Therapeutics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ptc Therapeutics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
54.86Buy7Odds
Ptc Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Ptc Therapeutics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ptc Therapeutics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ptc Therapeutics, talking to its executives and customers, or listening to Ptc Therapeutics conference calls.
Ptc Therapeutics Analyst Advice Details

Ptc Therapeutics Stock Analysis Indicators

Ptc Therapeutics stock analysis indicators help investors evaluate how Ptc Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ptc Therapeutics shares will generate the highest return on investment. By understating and applying Ptc Therapeutics stock analysis, traders can identify Ptc Therapeutics position entry and exit signals to maximize returns.
Quick Ratio1.53
Fifty Two Week Low25.01
Revenue Growth26.10%
Average Daily Volume Last 10 Day504.83k
Shares Short Prior Month5.62M
Average Daily Volume In Three Month786.83k
Shares Percent Shares Out7.90%
Gross Margins-1.80%
Forward Price Earnings-13.16
Short Percent Of Float11.04%
Float Shares64.45M
Fifty Two Week High49.88
Fifty Day Average37.32
Enterprise Value To Ebitda-10.23
Two Hundred Day Average38.10
Enterprise Value To Revenue5.36
Please check Your Equity Center. Note that the Ptc Therapeutics information on this page should be used as a complementary analysis to other Ptc Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Ptc Therapeutics Stock analysis

When running Ptc Therapeutics price analysis, check to measure Ptc Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ptc Therapeutics is operating at the current time. Most of Ptc Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ptc Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Ptc Therapeutics' price. Additionally, you may evaluate how the addition of Ptc Therapeutics to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Is Ptc Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ptc Therapeutics. If investors know Ptc Therapeutics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ptc Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ptc Therapeutics is measured differently than its book value, which is the value of Ptc Therapeutics that is recorded on the company's balance sheet. Investors also form their own opinion of Ptc Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ptc Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ptc Therapeutics' market value can be influenced by many factors that don't directly affect Ptc Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ptc Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Ptc Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ptc Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.